Coalition urges FDA to revoke Zohydro approval; UCSB picks up Novartis jab to ward off MenB;

@FiercePharma: GSK's new respiratory launches will give its revamped sales model a workout - FP. Story | Follow @FiercePharma

@TracyStaton: ICYMI: Thumbs up or down on megamergers? Depends on your point of view. More | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. News | Follow @EricPFierce

@CarlyHFierce: Yesterday's best-read on FP: Activists urge FDA to slap black-box warnings on lucrative testosterone boosters. Article | Follow @CarlyHFierce

> A coalition of healthcare, consumer and addiction treatment groups is pressing the FDA to revoke its approval of opioid painkiller Zohydro, which lacks abuse-deterrent characteristics. Story

> A second University, UC Santa Barbara, is now using Novartis' ($NVS) meningitis B vaccine to protect students and staff after an outbreak. More

> The FDA has approved AstraZeneca's ($AZN) Myalept to treat a rare metabolic disease. Release

> The U.K.'s cost watchdog has backed a new use for Bayer's Eylea, publishing final guidance that recommends the drug for use in macular edema patients. News

> Bayer said it will propose a dividend of €2.10 ($2.90) to investors, topping the 2.07 expected by analysts. Report

> Belgian pharma UCB saw revenue fall in 2013, but it expects that to turn around this year. Report

Medical Device News

@FierceMedDev: Foundation Medicine ended its first (partial) year as a public company revenue still heading higher. Release | Follow @FierceMedDev

@MarkHFierce: In the (marathon) battle to overturn the device tax, word from a pediatric device company CEO might help. More | Follow @MarkHFierce

@MichaelGFierce: FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. News | Follow @MichaelGFierce

@EmilyWFierce: Seno Medical Instruments raises $39M in a critical funding round for breast cancer dx device. More | Follow @EmilyWFierce

@GalenMoore: FDA may have gone too far, reading personal emails of medtech approval whistleblowers. Story | Follow @GalenMoore

> Qiagen has unveiled a low-tech HPV test in India. Piece

> A pediatric device company CEO speaks out against the device tax. More

Biotech News

@FierceBiotech: Novartis takes the transparency 'pledge,' but is it too little, too late? More | Follow @FierceBiotech

@JohnCFierce: Are Lily and J&J on the short list? Mystery U.S. pharma company circles Andromeda and its PhIII diabetes drug. Story | Follow @JohnCFierce

@DamianFierce: With a reported $330M+ on the way, Abingworth is the latest biotech VC amassing a new fund. News | Follow @DamianFierce

@EmilyMFierce: Trending at FierceBiotechResearch.com --> Scientist: Let's not discredit acid-bath stem cell studies--yet. More | Follow @EmilyMFierce

> Anika pops after the FDA finally approves its arthritis jab. Article

> Northwest Bio shoots for dendritic success where others have failed. Story

Diagnostics News

> Daktari Diagnostics is raising up to $30M to support its Africa HIV test launch. Story

> Loyola team zeros in on an early-stage heart attack biomarker. Research

> Diagnostic Biochips is pursuing angel funding for a microchip brain implant. News

> A massive review reaffirms fecal test's place in colon cancer Dx. Article

> Tumor DNA can serve as noninvasive biomarker to stage and help treat cancer. Article

> Ezose Sciences will explore glycans as a possible Parkinson's biomarker. Brief

Drug Delivery News

> Clustered nanoparticles deliver chemo to fight drug-resistant ovarian cancer. News

> Inner-ear delivery device sends drugs out, draws fluid in. More

> FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. Story

> Teva snags an EU recommendation for its asthma, COPD inhaler. Article

> Single microparticle holds 3 different drugs for a cancer 1-2-3 punch. Piece

> Nanoparticles deliver chemotherapy when hit with a targeted light. Item

Pharma Marketing News

> Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon. Analysis

> Endo's off-label Lidoderm mantra, whistleblower says: 'Put the patch where the pain is.' Story

> GSK's new respiratory launches will give its revamped sales model a workout. News

> Even for busy doctors, 'nothing is as good as a rep' for getting pharma info. Article

> Amarin's future dims further as FDA nixes 5-year Vascepa exclusivity. Story

> Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story

> Thrombogenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps? Brief

And Finally... A new analysis says that despite the falling number of new cases of bladder cancer in England, survival of the disease is worsening. More

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.